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Abstract: Necrotizing enterocolitis (NEC) is a critical intestinal emergency condition,
which mainly occurs in preterm very low birth weight (PVLBW) infants. Despite remarkable
advances in the care of PVLBW infants, with considerable improvement of the survival
rate in recent decades, the incidence of NEC and NEC-related mortality have not
declined accordingly. The fast progression from nonspecific signs to extensive necrosis also
makes primary prevention the first priority. Recently, increasing evidence has indicated
the important role of several nutrients in primary prevention of NEC. Therefore, the
aim of this review is to summarize some potential immunomodulatory nutrients in the
prevention of NEC, including bovine colostrum, probiotics, prebiotics (e.g., human milk
oligosaccharides), long chain polyunsaturated fatty acids, and amino acids (glutamine,
cysteine and N-acetylcysteine, L-arginine and L-citrulline). Based on current research
evidence, probiotics are the most documented effective method to prevent NEC, while others
still require further investigation in animal studies and clinical randomized controlled trials.
Keywords: necrotizing enterocolitis; very low birth weight infants; prevention;
nutrients; probiotics
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1. Introduction
Necrotizing enterocolitis (NEC) is an acute and potentially fatal disease characterized by
inflammation and necrosis in the gastrointestinal tract (GIT). Incidence of NEC is between 7% and 12%
in preterm very low birth weight (PVLBW) infants with an estimated mortality of 15%–30% [1]. The
pathogenesis of NEC is still incompletely understood, but it is thought that several factors are involved
interactively, such as premature birth, low birth weight, ischemia/reperfusion (I/R) injury, abnormal gut
bacterial colonization, and inappropriate enteral feeding [2] (Figure 1). Due to the obscure multifactorial
etiology, early diagnosis and effective treatment of NEC is limited. Consequently, effective strategies in
the prevention of NEC are critically needed.
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Figure 1. Possible mechanisms involved in the pathogenesis of NEC.
Many intestinal functions are affected by prematurity, which may predispose preterm infants to NEC.
These include GIT motility, mesenteric blood flow, digestive and absorptive functions, mucosal barrier
function, bacterial colonization, and gut immunity. Feeding strategies and nutritional interventions play
important roles in the modulation of these functions and thus the prevention of NEC [3]. Human
milk feeding has been shown to prevent NEC [4], whereas infant formula (IF) feeding is associated
with a higher risk of NEC, with a typical risk ratio of 2.77 (95% confidence interval (CI) 1.40 to 5.46) [5].
The superiority of human milk may be attributed to nutrients that can modulate the intestinal
digestive function, barrier function, bacterial colonization, and host immune defense, known as
immunonutrients [6]. Understanding of these nutrients is important in developing better nutritional
support for preterm infants, especially for those with limited access to human milk. Even in developed
countries like UK, Ireland, Canada, Australia, and New Zealand, only 7%–65% neonatal intensive
care units have access to human donor milk [7]. To summarize immunonutrients that may have clinical
potential in the prevention of NEC, a literature search was performed in PubMed, Embase, and Chinese
Biomedical Literature (CBM) databases with the focus on the following nutrients: bovine colostrum,
probiotics, human milk oligosaccharides, long chain polyunsaturated fatty acids, and % amino acids
(i.e., glutamine, cysteine and N-acetylcysteine, L-arginine nd L-citrulline). Both animal studies and
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clinical trials were reviewed to provide consideration of the clinical potentials of each nutrient. The
suggested NEC-preventive mechanisms of these nutrients are summarized in Table 1.
Table 1. NEC-preventive mechanisms.
Nutrients
Anti-
Inflammation
Anti-Oxidant
Stress
Regulating
Intestine
Blood Flow
Immuno-
Regulation
Improving
Gut Bacterial
Colonization
Improving
Intestine Cell
Growth and
Development
Bovine
colostrum
+ ´ ´ + + +
Probiotics ´ ´ ´ + + +
HMOs and
Prebiotics
+ ´ ´ + + ´
LCPUFAs + + ´ + ´ ´
Glutamine + + ´ ´ ´ +
Cysteine,
NAC
+ + ´ ´ ´ ´
Arginine/
citrulline
+ + + ´ ´ ´
HMOs, Human milk oligosaccharides; LCPUFAs, n-3 long chain polyunsaturated fatty acids; NAC,
N-acetylcysteine.
2. Bovine Colostrum
Bovine colostrum (BC) is the early milk from cows, which contains much higher amounts of trophic
and immuno-regulatory factors than those in IF (e.g., insulin-like growth factor, epidermal growth factor,
immunoglobulins, lactoferrin, transforming growth factor-β). These factors exert various physiological
functions including intestinal growth and development, intestinal defense, immuno-regulation, and
anti-infection [8]. The effect of BC in the prevention of NEC has been repeatedly documented in
preterm piglets, a well-established model for preterm infants [9]. When compared with human donor
milk, BC showed similar efficacy in decreasing incidence of NEC in pigs [10]. When used as minimal
enteral nutrition (MEN) just after preterm birth, BC markedly improved intestinal digestive and immune
functions, and prevented preterm pigs against NEC, relative to IF [11]. This indicates that BC may be
used as MEN for preterm infants while waiting for mothers to lactate.
Currently, the first clinical pilot trial is ongoing to investigate the safety and tolerability of BC as
the first enteral feeding for preterm infants and its primary effects on feeding tolerance and intestinal
functions, relative to IF and donor human milk (ClinicalTrials.gov, NCT02054091). The first part of the
study (twelve infants recruited) showed that BC was safe and well-tolerated [12]. If this study shows
promising results, further research is warranted to explore whether it can be used to prevent NEC in
PVLBW infants.
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3. Probiotics
During the past decades, probiotics have been studied extensively in the prevention of NEC. Six
recent meta-analyses confirmed the effectiveness of oral probiotics in reducing the incidences of NEC
and death [13–18]. Many level III neonatal centers in Finland, Italy and Japan have been routinely
using probiotics for over a decade and have not reported any significant adverse effects. However,
clinicians are still concerned about the efficacy and potential adverse effects and are facing challenges in
assessing which probiotics (or probiotic combinations) are the most effective ones for PVLBW infants.
Published studies have used a variety of different single or combined probiotic strains with different
target populations. Little is known about whether single-strain probiotics or probiotic combinations are
more effective in the prevention of NEC and death in PVLBW infants.
Recent articles have shown an association between NEC and a lack of gut microbiota diversity [19,20].
One review article suggested that probiotic combinations were more beneficial than single-strain
probiotics for gut and immune functions [21]. An updated meta-analysis including 21 trials (own
data, manuscript submitted) confirmed the preventive effects of probiotics on NEC and death showed
in previous systematic reviews. The updated meta-analysis focused on PVLWB or preterm infants
of ď34 weeks gestation (a high-risk group for NEC or death), who had undergone enteral administration
of probiotics commenced within the first seven days of life and continued for at least 28 days. Supported
by the results from a premature rat model [22], the meta-analysis showed that relative to single-strain
probiotics, probiotic combinations resulted in a marked reduction in NEC incidence, with a pooled
odds ratio (OR) of 0.37 (95% CI, 0.25–0.54; p < 0.00001) and mortality, with a pooled OR of 0.58
(95% CI, 0.43–0.79; p = 0.0006). The potential protective mechanisms might include increased diversity
of the intestinal microbiota, and perhaps suggest the potential benefit of offering healthy bacteria such
as Lactobacillus and Bifidobacterium to balance normal microbiota in this vulnerable population.
Based on the research evidence provided by randomized controlled trials (RCTs) and meta-analyses,
probiotics should be offered routinely to preterm infants at high risk of NEC, if safe and clinically
effective products are available.
4. Human Milk Oligosaccharides and Other Prebiotics
Human milk oligosaccharides (HMOs) are a family of structurally diverse glycans, which consists
of more than one hundred substances and presents in human milk at concentrations up to 20 g/L [23].
Studies in animals suggest that HMOs play a role in many important biological functions, such as shaping
intestinal microbiota composition as metabolic substrates [24,25], inhibiting the binding of pathogens to
the mucosal epithelium as soluble decoy receptors [26,27], and dampening excessive mucosal leukocyte
infiltration and activation as modulators [23,25,28,29]. However, studies showed that HMOs may favor
clostridial population in the distal part of the intestine when fed to mice, and feeding sialyl(α2,3)lactose
to interleukin 10-deficient mice increased colitis severity [30,31].
Recent rat studies showed that protective effects of HMOs against NEC were due to a specific isomer of
disialyllacto-N-tetraose (DSLNT), and a synthetic HMO-mimicking prebiotics, galacto-oligosaccharides
(GOS), had no effects in NEC prevention. This indicates that the protective effect of HMOs against NEC
may be highly structure-specific, as GOS is very different from DSLNT in its chemical structure [29].
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However, DSLNT is not easily obtained by either purification or synthesis due to the limited availability
of human milk and low abundance in bovine milk [32]. Two novel disialyl hexasaccharides,
disialyllacto-N-neotetraose (DSLNnT) and α2-6-linked disialyllacto-N-tetraose (DS’LNT), are readily
available by enzymatic synthesis. They have been shown to protect neonatal rats against NEC [28]. One
clinical study indicated that low concentrations of DSLNT in 4-day mother’s milk were associated with
increased risk of NEC in PVLBW infants with HIV-infected mothers (200 ˘ 126 vs. 345 ˘ 186 µg/mL;
p < 0.05) [33].
Effects of other prebiotics, such as GOS, fructo oligosaccharide (FOS), lactulose, and inulin, have
been studied in clinical trials. The most recent meta-analysis on prebiotics showed no effects on NEC in
preterm infants [24]. A multi-center study, ProPre-Save further confirmed that using prebiotics (inulin)
alone failed to reduce the incidence of NEC (Bell stage ě2) in PVLBW infants compared with placebo
(12% vs. 18%; p > 0.05), although it had positive effects on feeding tolerance, sepsis, and mortality [34].
A recent study showed that addition of GOS/FOS mixture to breast milk significantly reduced the
incidence of NEC (4.0% vs. 22.0%; hazard ratio: 0.49 (95% CI: 0.29–0.84); p = 0.002) and time to full
enteral feeds (average of 11 (7–21) vs. average of 14 (8–36) days; p = 0.02) in exclusively breast-milk fed
PVLBW infants [35]. However, in this study only one infant developed NEC with Bell stage >1, which
indirectly supports the findings of the meta-analysis and the ProPre-Save study. More animal studies
and clinical RCTs are needed to fully evaluate the effects of HMOs including DSLNnT and DS’LNT as
promising therapeutic candidates in NEC prevention.
5. Long Chain Polyunsaturated Fatty Acids
Apart from the nutritional value for visual and cognitive development, n-3 long chain polyunsaturated
fatty acids (LCPUFAs, e.g., docosahexaenoic acid, DHA) and n-6 LCPUFAs (e.g., arachidonic acid, AA)
have versatile biological effects on immune-modulation and inflammatory response [36]. Since nearly
90% of fetal fat deposition occurs during the last 10 weeks of gestation, and accretion of LCPUFAs
increases markedly during the last trimester of gestation, earlier premature birth implies greater LCPUFA
deficiency and greater need for LCPUFA supplementation.
LCPUFA supplementation reduced the incidence of NEC in an experimental neonatal rat model of
NEC [37]. This effect may be due to the functions in maintaining the epithelial integrity, reducing
bacterial and endotoxin translocation, and decreasing mucosal platelet-activating factor synthesis and
receptor activation [38]. Furthermore, DHA has been shown to reduce lipopolysaccharide-induced
nuclear factor (NF)-κB activation and IL-6 production in mice [39]. A recent study also showed that
n-3 fatty acids are beneficial for protecting the premature intestine from inflammation by regulating
eicosanoid- and NF-κB-related metabolite expression in premature rat pups [40]. These results suggest
that LCPUFAs modulate various key factors involved in experimental NEC pathogenesis and partially
explain why LCPUFAs have the protective effect on neonatal NEC.
In preterm infants, decreased postnatal DHA and AA in blood hads been associated with neonatal
morbidities [41]. A recent meta-analysis disclosed that n-3 LCPUFAs supplementation were associated
with a trend toward reduced risk of NEC (pooled relative risk 0.50, 95% CI 0.23–1.10, five studies,
n = 900 infants) in infants born at ď32 weeks gestation without detrimental effect [42]. Large-scale
interventional studies are still required to define the clinical benefits of LCPUFA in PVLBW infants.
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6. Glutamine
Glutamine (Gln) is an important nutrient for intestinal cell proliferation and small intestinal growth [43].
Studies in cell and animal experiments indicated that Gln exerts multiple biological activities such
as antioxidant, anti-apoptosis, and anti-inflammation, which are involved in the pathophysiological
mechanism of NEC [44,45]. Enteral supplementation of Gln attenuated local intestinal inflammatory
damage in rats with NEC [43]. A recent study also found that Gln markedly reduced the mucosal injury
by suppressing the expression of toll-like receptor (TLR) 2/4 and caspace-3 in the ileum and colon of
neonatal rats with NEC, as TLRs play key roles in the pathogenesis of NEC [46,47].
Gln supplementation has been investigated in premature infants in a wide variety of clinical settings.
Gln-supplemented parenteral nutrition (PN) for PVLBW infants has been showed to decrease NEC
incidence compared with a standard PN solution (0/25 vs. 5/30; p < 0.01) [48]. However, meta-analysis
and several subsequent trials did not verify the effect [49–51]. A recent study showed that enteral
supplementation of Gln was safe and could significantly reduce feeding intolerance (p = 0.015) in
PVLBW infants in the first days or weeks of life. There was also a tendency towards lowered risk
of NEC and intestinal perforation, but the differences did not reach statistical significance [52].
The discrepancy between pronounced protective effects in animal models and negative results in
clinical trials warrants further well-designed multicenter RCTs with adequately powered sample size to
clarify the role of Gln as a preventive agent against NEC in PVLBW infants.
7. Cysteine and N-Acetylcysteine
N-acetylcysteine (NAC), the precursor of cysteine, is an important component in the production of
intracellular glutathione [53]. Premedication with NAC was associated with less severe NEC lesions in
an intraluminal casein-induced NEC model using neonatal piglets [54]. In another neonatal rat model of
NEC, NAC showed a protective effect on intestinal injury through its anti-inflammatory and antioxidant
properties [55]. This effect was also demonstrated in two recent studies in experimental animals [56,57].
Few trials have assessed the effects of cysteine or NAC on NEC in preterm infants as primary
outcomes. One Cochrane review concluded that routine addition of short-term cysteine treatment
improves nitrogen balance in preterm infants, but it does not support routine NAC supplementation
for PVLBW infants. Thus, more investigations are needed to evaluate whether cysteine or NAC
supplementation affects NEC outcomes in preterm infants [58].
8. L-Arginine and L-Citrulline
Nitric oxide (NO) plays an essential role in NEC development by regulating vasodilatation and
blood flow to the intestine [59,60]. Endogenous NO originates from the metabolism of L-arginine and
L-citrulline, indicating their potential effects on NEC prevention (Figure 2). Low citrulline concentration
has been reported in preterm infants [61,62] and piglets with NEC [63]. However, a recent study reported
that low citrulline concentration in routinely collected neonatal dried blood spots was not associated with
NEC [64]. There is no animal or clinical study assessing citrulline supplementation on NEC prevention.
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Figure 2. Possible mechanisms involved in the pathogenesis of Necrotizing enterocolitis
(NEC). ASS, argininosuccinate synthase; ASL, argininosuccinate lyase; NO, nitric oxide;
NOS, nitric oxide synthase.
Arginine, an essential amino acid for neonates, is exclusively synthesized by intestinal epithelial
cells [65]. Low levels of plasma arginine in preterm infants are associated with increased incidence
of NEC [62,66]. In several animal models of NEC, L-arginine supplementation has been proven to
play pivotal roles in attenuation of intestinal injury by the L-arginine-NO pathway. For example,
in the eonatal piglet NEC model, intravenous fusion of L-arginine markedly alleviat d intes inal
injury [67], and enteral s pplementation of L-arginin increased intestinal mucosal growth [65]. I
another ischemia/reperfusion induced NEC model in mice, dietary supplementation with L-arginine and
L-carnitine attenuated the histological intestinal injury and significantly decreased lipid peroxidation in
bowel injury [68].
Parenteral arginine supplementation in preterm infants increased plasma arginine levels and decreased
NEC (6.7% vs. 27.3%; p < 0.01) in premature infants [69]. However, the outcome was confounded by
the presence of many stage I NEC cases in the control group. In another double-blind RCT, enteral
supplementation of L-arginine from day 3 to 28 after birth reduced the incidence of stage III NEC
compared with placebo group [70]. A meta-analysis with 425 PVLBW infants enrolled showed a
60% reduction in all stages of NEC (RR 0.40, 95% CI 0.23 to 0.69, NNT = 5, p = 0.001) by arginine
supplementation compared with placebo and a 59% reduction in the incidence of stage II and III NEC
(RR 0.41, 95% CI 0.20 to 0.85, number needed to treat = 9, p = 0.02). It was concluded that L- rginine
supplementation appeared to be protectiv against NEC without adverse effects in preterm infa ts [71].
Based on these findings, L-arginine supplementation deserves to be consi ered as a novel and
potentially cost-effective method to prevent NEC. However, large multi-center RCTs are needed before
this can become a common practice.
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9. Discussion
NEC is a multifactorial disease with relatively high mortality, and its pathophysiology remains
unclear. Several factors appear to contribute to the development of NEC, including immaturity of
multiple intestinal functions, altered anti-inflammatory control, abnormal gut bacterial colonization,
inappropriate enteral feeding and impaired host defense. The above-discussed immunonutrients have been
shown in animal models to exert various physiological effects on intestinal growth and development,
intestinal defense, immune-modulation and inflammatory response. These promising findings point
toward the application of these nutrients as useful clinical tools. Some of these nutrients have been
applied in clinical practices (e.g., probiotics) while others are still in the research stage (e.g., bovine
colostrum). Although the effectiveness of probiotics in the prevention of NEC has been confirmed by
various clinical trials and meta-analyses, there are still remaining questions in terms of the optimal strain
or strain combinations, timing, dose, and duration of therapy. Further comparative studies are required
to provide better clinical guidelines for probiotic therapy in preterm infants.
10. Conclusions
Enteral supplementation of probiotics is evident in NEC prevention, but clinical guidelines in terms of
timing, strains, dose, length of therapy, and contraindications are urgently needed for PVLBW. Bovine
colostrum seems to be a promising diet in replacement of IF to stimulate the development of the immature
intestine while waiting for the mother’s own milk during the first days of life. LCPUFAs and HMOs
might be directly supplemented to human milk or used to produce better preterm IF for those who have
limited access to human milk. The aforementioned amino acids and LCPUFA might also be added to
parenteral nutrition preparations. Clearly, more animal studies and clinical trials are required to further
investigate the biological functions and to verify the safety and effectiveness of supplementation with
immunonutrients in NEC prevention in PVLBW infants before recommendation of their routine use in
the clinics (Table 2).
Table 2. Evidences of nutritional supplementation in the prevention of NEC.
Nutrients
Clinical Trials (Authors,
Reference No.)
Outcomes
Primary Secondary
Bovine
colostrum
Yanqi Li et al., [12] safe and well tolerated Ò enteral protein intake
Probiotics
Alfaleh K et al., 2010. [15] Ósevere NEC and mortality no reduction on sepsis
and days on TPN
Deshpande G et al., 2010. [16] Ómortality and 30% NEC no reduction on sepsis
Wang Q et al., 2012. [17] ÓNEC and mortality no reduction on sepsis
Alfaleh K et al., 2014. [18] ÓNEC and mortality no reduction on sepsis
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Table 2. Cont.
Nutrients
Clinical Trials (Authors,
Reference No.)
Outcomes
Primary Secondary
HMOs or
Prebiotics
Van Niekerk E et al., 2014. [33]
low concentrations of
DSLNT were associated
with NECÒ
NA
Dilli D et al., 2015. [34] failed to reduce NEC
Ótime to full enteral feeding,
sepsis, mortality and stays
in NICU
Armanian AM et al., 2014. [35] ÓNEC Ótime to full enteral feeds and
duration of hospitalization
LCPUFAs Zhang P et al., 2014. [42]
ÓNEC in infants born at
ď32 weeks gestation
ÓBPD in infants born at
ď32 weeks gestation
Glutamine
Bober-Olesin´ska K et al.,
2005. [48]
ÓNEC no reduction on sepsis
and stays in NICU
Sevastiadou S et al., 2011. [50] ÓNEC Ósepsis
Tubman TR et al., 2008. [49] no effect on mortality
no effect on NEC, infection,
time to full enteral nutrition,
or duration of hospitalization
Mohamad Ikram I et al., 2011. [51] no reduction on NEC
no reduction on sepsis, duration
of ventilation, and NICU stay
Pawlik, D et al., 2011. [52] ÓFeeding intolerance
lower but no significant
differences in NEC, sepsis
and intestinal perforation
Cysteine or
NAC
Soghier LM et al., 2006. [58]
ÒNitrogen retention
No differences on growth
no reduction on death, NEC,
BPD, ROP, IVH, PVL
L-Arginine,
L-citrulline
Amin HJ et al., 2002. [69]
ÓNEC, Òplasma
arginine levels
no differences in nutrient intake,
plasma ammonia and amino
acid concentrations
Polycarpou E et al., 2013. [70] ÓNEC stage III NA
Mitchell K et al., 2014. [71]
Ó60% all stage NEC and
59% NEC stage II and III
no difference in any
neurodevelopmental
disability at 3 years
NEC: necrotizing enterocolitis; TPN: total parenteral nutrition; BPD: bronchopulmonary dysplasia; NICU:
neonatal intensive Crtinopathy of prematurity care unit; ROP: retinopathy of prematurity; IVH:intraventricular
hemorrhage; PVL: periventricular leukomalacia.
Abbreviations
Necrotizing enterocolitis (NEC); preterm very low birth weight infants (PVLBW); gastrointestinal
tract (GIT); bovine colostrum (BC); infant formula (IF); human milk oligosaccharides (HMOs);
disialyllacto-N-tetraose (DSLNT); randomized controlled trials (RCTs); long chain polyunsaturated
fatty acids (LCPUFAs); docosahexaenoic acid (DHA); arachidonic acid (AA); glutamine (Gln);
n-acetylcysteine (NAC); nitric oxide (NO); odds ratio (OR); confidence interval (CI).
Nutrients 2015, 7 7265
Author Contributions
Ping Zhou and Hung-Chih Lin performed the search for literature and wrote the manuscript.
Yanqi Li and Li-Ya Ma were involved in the conception of the review. All authors reviewed, commented
on and approved the final version.
Conflicts of Interest
The authors declare no conflict of interest.
References
1. Neu, J.; Walker, W.A. Necrotizing enterocolitis. N. Engl. J. Med. 2011, 364, 255–264. [CrossRef]
[PubMed]
2. Chen, A.C.; Chung, M.Y.; Chang, J.H.; Lin, H.C. Pathogenesis implication for necrotizing
enterocolitis prevention in preterm very-low-birth-weight infants. J. Pediatr. Gastroenterol. Nutr.
2014, 58, 7–11. [CrossRef] [PubMed]
3. Ramani, M.; Ambalavanan, N. Feeding practices and necrotizing enterocolitis. Clin. Perinatol.
2013, 40, 1–10. [CrossRef] [PubMed]
4. Cristofalo, E.A.; Schanler, R.J.; Blanco, C.L. Randomized trial of exclusive human milk versus
preterm formula diets in extremely premature infants. J. Pediatr. 2013, 163, 1592–1595.
[CrossRef] [PubMed]
5. Quigley, M.A.; Henderson, G.; Anthony, M.Y. Formula milk versus donor breast milk for feeding
preterm or low birth weight infants. Cochrane. Database. Syst. Rev. 2007. [CrossRef]
6. Ballard, O.; Morrow, A.L. Human milk composition: Nutrients and bioactive factors. Pediatr. Clin.
N. Am. 2013, 60, 49–74. [CrossRef] [PubMed]
7. Klingenberg, C.; Embleton, N.D.; Jacobs, S.E.; O’Connell, L.A.; Kuschel, C.A. Enteral feeding
practices in very preterm infants: An international survey. Arch. Dis. Child. Fetal Neonatal. Ed.
2012, 97, F56–F61. [CrossRef] [PubMed]
8. Chatterton, D.E.; Nguyen, D.N.; Bering, S.B.; Sangild, P.T. Anti-inflammatory mechanisms of
bioactive milk proteins in the intestine of newborns. Int. J. Biochem. Cell Biol. 2013, 45,
1730–1747. [CrossRef] [PubMed]
9. Siggers, R.H.; Siggers, J.; Thymann, T.; Boye, M.; Sangild, P.T. Nutritional modulation of the gut
microbiota and immune system in preterm neonates susceptible to necrotizing enterocolitis. J. Nutr.
Biochem. 2011, 22, 511–521. [CrossRef] [PubMed]
10. Jensen, M.L.; Sangild, P.T.; Lykke, M.; Schmidt, M.; Boye, M.; Jensen, B.B.; Thymann, T.
Similar efficacy of human banked milk and bovine colostrum to decrease incidence of necrotizing
enterocolitis in preterm piglets. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013, 305, R4–R12.
[CrossRef] [PubMed]
11. Shen, R.L.; Thymann, T.; Østergaard, M.V. Early gradual feeding with bovine colostrum improves
gut function and NEC resistance relative to infant formula in preterm pigs. Am. J. Physiol.
Gastrointest. Liver Physiol. 2015. [CrossRef] [PubMed]
Nutrients 2015, 7 7266
12. Li, Y.; Petersen, S.M.; Ye, X.; Shen, R.L.; Sangild, P.T.; Greisen, G.O. Bovine colostrum to
supplement the first enteral feeding in preterm infants: A pilot feasibility study (PreColos). Pediatr.
Res.. submitted for publication.
13. Barclay, A.R.; Stenson, B.; Simpson, J.H.; Weaver, L.T.; Wilson, D.C. Probiotics for necrotizing
enterocolitis: A systematic review. J. Pediatr. Gastroenterol. Nutr. 2007, 45, 569–576. [CrossRef]
[PubMed]
14. Deshpande, G.; Rao., S.; Patole, S. Probiotics for prevention of necrotizing enterocolitis in preterm
neonates with very low birth weight: A systematic review of randomised controlled trials. Lancet
2007, 369, 1614–1620. [CrossRef]
15. Alfaleh, K.; Anabrees, J.; Bassler, D. Probiotics reduce the risk of necrotizing enterocolitis in
preterm infants: A meta-analysis. Neonatology 2010, 97, 93–99. [CrossRef] [PubMed]
16. Deshpande, G.; Rao, S.; Patole, S.; Bulsara, M. Updated meta-analysis of probiotics for preventing
necrotizing enterocolitis in preterm neonates. Pediatrics 2010, 125, 921–930. [CrossRef]
[PubMed]
17. Wang, Q.; Dong, J.; Zhu, Y. Probiotic supplement reduces risk of necrotizing enterocolitis and
mortality in preterm very low-birth-weight infants: An updated meta-analysis of 20 randomized,
controlled trials. J. Pediatr. Surg. 2012, 47, 241–248. [CrossRef] [PubMed]
18. Alfaleh, K.; Anabrees, J.; Bassler, D.; Al-Kharfi, T. Probiotics for prevention of necrotizing
enterocolitis in preterm infants. Cochrane Database Syst. Rev. 2014, 4. [CrossRef]
19. Carlisle, E.M.; Morowitz, M.J. The intestinal microbiome and necrotizing enterocolitis. Curr.
Opin. Pediatr. 2013, 25, 382–387. [CrossRef] [PubMed]
20. Shiou, S.R.; Yu, Y.; Guo, Y.; He, S.M.; Mziray-Andrew, C.H.; Hoenig, J.; Sun, J.; Petrof, E.O.;
Claud, E.C. Synergistic protection of combined probiotic conditioned media against neonatal
necrotizing enterocolitis-like intestinal injury. PLoS ONE 2013, 8, e65108. [CrossRef] [PubMed]
21. Chapman, C.M.; Gibson, G.R.; Rowland, I. Health benefits of probiotics: Are mixtures more
effective than single strains? Eur. J. Nutr. 2011, 50, 1–17. [CrossRef] [PubMed]
22. Wu, S.F.; Chiu, H.Y.; Chen, A.C.; Lin, H.Y.; Lin, H.C.; Michael, C. Efficacy of different
probiotic combinations on death and necrotizing enterocolitis in a premature rat model. J. Pediatr.
Gastroenterol. Nutr. 2013, 57, 23–28. [CrossRef] [PubMed]
23. Bode, L. Human milk oligosaccharides: Every baby needs a sugar mama. Glycobiology 2012, 22,
1147–1162. [CrossRef] [PubMed]
24. Srinivasjois, R.; Rao, S.; Patole, S. Prebiotic supplementation of formula in preterm neonates:
Updated systematic review and meta-analysis of randomised controlled trials. Clin. Nutr. 2013, 32,
958–965. [CrossRef] [PubMed]
25. Chichlowski, M.; German, J.B.; Lebrilla, C.B.; Mills, D.A. The influence of milk oligosaccharides
on the microbiota of infants: Opportunities for formulas. Annu. Rev. Food Sci. Technol. 2011, 2,
331–351. [CrossRef] [PubMed]
26. Quintero, M.; Maldonado, M.; Perez-Munoz, M.; Jimenez, R.; Fangman, T.; Rupnow, J.;
Wittke, A.; Russell, M.; Hutkins, R. Adherence Inhibition of Cronobacter sakazakii to Intestinal
Epithelial Cells by Prebiotic Oligosaccharides. Curr. Microbiol. 2011, 62, 1448–1454. [CrossRef]
[PubMed]
Nutrients 2015, 7 7267
27. Newburg, D.S.; Ruiz-Palacios, G.M.; Morrow, A.L. Human milk glycans protect infants against
enteric pathogens. Annu. Rev. Nutr. 2005, 25, 37–58. [CrossRef] [PubMed]
28. Yu, H.; Lau, K.; Thon, V.; Autran, C.A.; Jantscher-Krenn, E.; Xue, M.; Li, Y.; Sugiarto, G.; Qu, J.;
Mu, S.; et al. Synthetic disialyl hexasaccharides protect neonatal rats from necrotizing enterocolitis.
Angew. Chem. Int. Ed. Engl. 2014, 53, 6687–6691. [CrossRef] [PubMed]
29. Jantscher-Krenn, E.; Zherebtsov, M.; Nissan, C.; Goth, K.; Guner, Y.S.; Naidu, N.; Choudhury, B.;
Grishin, A.V.; Ford, H.R.; Bode, L.; et al. The human milk oligosaccharide disialyllacto-N-tetraose
prevents necrotizing enterocolitis in neonatal rats. Gut 2012, 61, 1417–1425. [CrossRef] [PubMed]
30. Mielcarek, C.; Romond, P.C.; Romond, M.B.; Bezirtzoglou, E. Modulation of bacterial
translocation in mice mediated through lactose and human milk oligosaccharides. Anaerobe 2011,
17, 361–366. [CrossRef] [PubMed]
31. Kurakevich, E.; Hennet, T.; Hausmann, M.; Rogler, G.; Borsig, L. Milk oligosaccharide sialyl
(α2,3)lactose activates intestinal CD11c+ cells through TLR4. Proc. Natl. Acad. Sci. USA 2013,
110, 17444–17449. [CrossRef] [PubMed]
32. Aldredge, D.L.; Geronimo, M.R.; Hua, S. Annotation and structural elucidation of bovine milk
oligosaccharides and determination of novel fucosylated structures. Glycobiology 2013, 23,
664–676. [CrossRef] [PubMed]
33. Van Niekerk, E.; Autran, C.A.; Nel, D.G.; Kirsten, G.F.; Blaauw, R.; Bode, L. Human milk
oligosaccharides differ between HIV-Infected and HIV-Uninfected mothers and are related to
necrotizing enterocolitis incidence in their preterm very-low-birth-weight infants. J. Nutr. 2014,
144, 1227–1233. [CrossRef] [PubMed]
34. Dilli, D.; Aydin, B.; Fettah, N.D. The ProPre-Save Study: Effects of Probiotics and Prebiotics
Alone or Combined on Necrotizing Enterocolitis in Very Low Birth Weight Infants. J. Pediatr.
2015, 166, 545–551. [CrossRef] [PubMed]
35. Armanian, A.M.; Sadeghnia, A.; Hoseinzadeh, M. The effect of neutral oligosaccharides on
reducing the incidence of necrotizing enterocolitis in preterm infants: A randomized clinical trial.
Int. J. Prev. Med. 2014, 5, 1387–1395. [PubMed]
36. Kelley, D.S. Modulation of human immune and inflammatory responses by dietary fatty acids.
Nutrition 2001, 17, 669–673. [CrossRef]
37. Caplan, M.S.; Russell, T.; Xiao, Y.; Amer, M.; Kaup, S.; Jilling, T. Effect of polyunsaturated fatty
acid (PUFA) supplementation on intestinal inflammation and necrotizing enterocolitis (NEC) in a
neonatal rat model. Pediatr. Res. 2001, 49, 647–652. [CrossRef] [PubMed]
38. Caplan, M.S.; Jilling, T. The role of polyunsaturated fatty acid supplementation in intestinal
inflammation and neonatal necrotizing enterocolitis. Lipids 2001, 36, 1053–1057. [CrossRef]
[PubMed]
39. Lee, J.Y.; Zhao, L.; Youn, H.S.; Weatherill, A.R.; Tapping, R.; Feng, L.; Lee, W.H.;
Fitzgerald, K.A.; Hwang, D.H. Saturated fatty acid activates but polyunsaturated fatty acid inhibits
Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J. Biol. Chem. 2004, 279,
16971–16979. [CrossRef] [PubMed]
Nutrients 2015, 7 7268
40. Ohtsuka, Y.; Okada, K.; Yamakawa, Y.; Ikuse, T.; Baba, Y.; Inage, E.; Fujii, T.; Izumi, H.;
Oshida, K.; Nagata, S.; et al. ω-3 fatty acids attenuate mucosal inflammation in premature rat
pups. J. Pediatr. Surg. 2011, 46, 489–495. [CrossRef] [PubMed]
41. Martin, C.R.; Dasilva, D.A.; Cluette-Brown, J.E.; Dimonda, C.; Hamill, A.; Bhutta, A.Q.
Decreased postnatal docosahexaenoic and arachidonic acid blood levels in premature infants are
associated with neonatal morbidities. J. Pediatr. 2011, 159, 743–749. [CrossRef] [PubMed]
42. Zhang, P.; Lavoie, P.M.; Lacaze-Masmonteil, T.; Rhainds, M.; Marc, I. Omega-3 long-chain
polyunsaturated fatty acids for extremely preterm infants: A systematic review. Pediatrics 2014,
134, 120–134. [CrossRef] [PubMed]
43. Dilsiz, A.; Ciftçi, I.; Aktan, T.M.; Gürbilek, M.; Karagözog˘lu, E. Enteral glutamine
supplementation and dexamethasone attenuate the local intestinal damage in rats with experimental
necrotizing enterocolitis. Pediatr. Surg. Int. 2003, 19, 578–582. [CrossRef] [PubMed]
44. Marc Rhoads, J.; Wu, G. Glutamine, arginine, and leucine signaling in the intestine. Amino Acids
2009, 37, 111–122. [CrossRef] [PubMed]
45. Wang, J.; Chen, L.; Li, P. Gene expression is altered in piglet small intestine by weaning and dietary
glutamine supplementation. J. Nutr. 2008, 138, 1025–1032. [PubMed]
46. Hackam, D.J.; Good, M.; Sodhi, C.P. Mechanisms of gut barrier failure in the pathogenesis of
necrotizing enterocolitis: Toll-like receptors throw the switch. Semin. Pediatr. Surg. 2013, 22,
76–82. [CrossRef] [PubMed]
47. Zhou, W.; Li, W.; Zheng, X.H.; Rong, X.; Huang, L.G. Glutamine downregulates TLR-2 and TLR-4
expression and protects intestinal tract in preterm neonatal rats with necrotizing enterocolitis.
J. Pediatr. Surg. 2014, 49, 1057–1063. [CrossRef] [PubMed]
48. Bober-Olesin´ska, K.; Kornacka, M.K. Effects of glutamine supplemented parenteral nutrition on
the incidence of necrotizing enterocolitis, nosocomial sepsis and length of hospital stay in very low
birth weight infants. Med. Wieku. Rozwojowego 2005, 9, 325–333.
49. Tubman, T.R.; Thompson, S.W.; McGuire, W. Glutamine supplementation to prevent morbidity
and mortality in preterm infants. Cochrane Database. Syst. Rev. 2008. [CrossRef]
50. Sevastiadou, S.; Malamitsi-Puchner, A.; Costalos, C.; Skouroliakou, M.; Briana, D.D.;
Antsaklis, A.; Roma-Giannikou, E. The impact of oral glutamine supplementation on the
intestinal permeability and incidence of necrotizing enterocolitis/septicemia in premature neonates.
J. Matern. Fetal Neonatal Med. 2011, 24, 1294–1300. [CrossRef] [PubMed]
51. Mohamad Ikram, I.; Quah, B.S.; Noraida, R.; Djokomuljanto, S.; Faris Irfan, C.Y.;
van Rostenberghe, H. A randomised controlled trial of glutamine-enriched neonatal parenteral
nutrition in Malaysia. Singap. Med. J. 2011, 52, 356–360.
52. Pawlik, D.; Lauterbach, R.; Hurkała, J.; Radziszewska, R. The effects of enteral administration of
glutamine enriched solution in very low birth weight infants on reducing the symptoms of feeding
intolerance, a prospective, randomized pilot study. Med. Wieku. Rozwojowego 2012, 16, 205–211.
53. Faintuch, J.; Aguilar, P.B.; Nadalin, W. Relevance of N-acetylcysteine in clinical practice:
Fact, myth or consequence? Nutrition 1999, 15, 177–179. [CrossRef]
Nutrients 2015, 7 7269
54. Koivusalo, A.; Kauppinen, H.; Anttila, A.; Rautelin, H.; Jusufovic, J.; Lindahl, H.; Rintala, R.
Intraluminal casein model of necrotizing enterocolitis for assessment of mucosal destruction,
bacterial translocation, and the effects of allopurinol and N-acetylcysteine. Pediatr. Surg. Int.
2002, 18, 712–717. [PubMed]
55. Ozdemir, R.; Yurttutan, S.; Sar, F.N.; Uysal, B.; Unverdi, H.G.; Canpolat, F.E.; Erdeve, O.;
Dilmen, U. Antioxidant effects of N-acetylcysteine in a neonatal rat model of necrotizing
enterocolitis. J. Pediatr. Surg. 2012, 47, 1652–1657. [CrossRef] [PubMed]
56. Tayman, C.; Tonbul, A.; Kosus, A.; Hirfanoglu, I.M.; Uysal, S.; Haltas, H.; Tatli, M.M.; Andiran, F.
N-acetylcysteine may prevent severe intestinal damage in necrotizing enterocolitis. J. Pediatr. Surg.
2012, 47, 540–550. [CrossRef] [PubMed]
57. Hou, Y.; Wang, L.; Yi, D.; Ding, B.; Yang, Z.; Li, J.; Chen, X.; Qiu, Y.; Wu, G. N-acetylcysteine
reduces inflammation in the small intestine by regulating redox, EGF and TLR4 signaling. Amino
Acids 2013, 45, 513–522. [CrossRef] [PubMed]
58. Soghier, L.M.; Brion, L.P. Cysteine, cystine or N-acetylcysteine supplementation in parenterally
fed neonates. Cochrane Database Syst. Rev. 2006. [CrossRef]
59. Ciftçi, I.; Dilsiz, A.; Aktan, T.M.; Gürbilek, M.; Duman, S. Effects of nitric oxide synthase
inhibition on intestinal damage in rats with experimental necrotizing enterocolitis. Eur. J. Pediatr.
Surg. 2004, 14, 398–403. [CrossRef] [PubMed]
60. Yazji, I.; Sodhi, C.P.; Lee, E.K.; Good, M.; Egan, C.E.; Afrazi, A.; Neal, M.D.; Jia, H.; Lin, J.;
Ma, C.; et al. Endothelial TLR4 activation impairs intestinal microcirculatory perfusion in
necrotizing enterocolitis via eNOS-NO-nitrite signaling. Proc. Natl. Acad. Sci. USA 2013, 110,
9451–9456. [CrossRef] [PubMed]
61. Ioannou, H.P.; Diamanti, E.; Piretzi, K. Plasma citrulline levels in preterm neonates with
necrotizing enterocolitis. Early Hum. Dev. 2012, 88, 563–566. [CrossRef] [PubMed]
62. Celik, I.H.; Demirel, G.; Canpolat, F.E.; Dilmen, U. Reduced plasma citrulline levels in low birth
weight infants with necrotizing enterocolitis. J. Clin. Lab. Anal. 2013, 27, 328–332. [CrossRef]
[PubMed]
63. Jiang, P.; Wan, J.M.; Cilieborg, M.S.; Sit, W.H.; Sangild, P.T. Premature delivery reduces intestinal
cytoskeleton, metabolism, and stress response proteins in newborn formula-fed pigs. J. Pediatr.
Gastroenterol. Nutr. 2013, 56, 615–622. [CrossRef] [PubMed]
64. Englund, A.; Rogvi, R.A.; Melgaard, L.; Greisen, G. Citrulline concentration in routinely collected
neonatal dried blood spots cannot be used to predict necrotising enterocolitis. Acta Paediatr. 2014,
103, 1143–1147. [CrossRef] [PubMed]
65. Puiman, P.J.; Stoll, B.; van Goudoever, J.B.; Burrin, D.G. Enteral arginine does not increase
superior mesenteric arterial blood flow but induces mucosal growth in neonatal pigs. J. Nutr. 2011,
141, 63–70. [CrossRef] [PubMed]
66. Richir, M.C.; Siroen, M.P.; van Elburg, R.M.; Fetter, W.P.; Quik, F.; Nijveldt, R.J.; Heij, H.A.
Low plasma concentrations of arginine and asymmetric dimethylarginine in premature infants with
necrotizing enterocolitis. Br. J. Nutr. 2007, 97, 906–911. [CrossRef] [PubMed]
67. Di Lorenzo, M.; Bass, J.; Krantis, A. Use of L-arginine in the treatment of experimental necrotizing
enterocolitis. J. Pediatr. Surg. 1995, 30, 235–240. [CrossRef]
Nutrients 2015, 7 7270
68. Akisu, M.; Ozmen, D.; Baka, M.; Habif, S.; Yalaz, M.; Arslanoglu, S.; Kultursay, N.;
Bayindir, O. Protective effect of dietary supplementation with L-arginine and L-carnitine on
hypoxia/reoxygenation-induced necrotizing enterocolitis in young mice. Biol. Neonate 2002, 81,
260–265. [CrossRef] [PubMed]
69. Amin, H.J.; Zamora, S.A.; McMillan, D.D.; Fick, G.H.; Butzner, J.D.; Parsons, H.G.; Scott, R.B.
Arginine supplementation prevents necrotizing enterocolitis in the premature infant. J. Pediatr.
2002, 140, 425–431. [CrossRef] [PubMed]
70. Polycarpou, E.; Zachaki, S.; Tsolia, M.; Papaevangelou, V.; Polycarpou, N.; Briana, D.D.;
Gavrili, S.; Kostalos, C.; Kafetzis, D. Enteral L-arginine supplementation for prevention of
necrotizing enterocolitis in very low birth weight neonates: A double-blind randomized pilot study
of efficacy and safety. J. Parenter. Enter. Nutr. 2013, 37, 617–622. [CrossRef] [PubMed]
71. Mitchell, K.; Lyttle, A.; Amin, H.; Shaireen, H.; Robertson, H.L.; Lodha, A.K. Arginine
supplementation in prevention of necrotizing enterocolitis in the premature infant: An updated
systematic review. BMC Pediatr. 2014, 14. [CrossRef] [PubMed]
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/4.0/).
